You could be right. But I'd have thought the opposite makes more sense.
Gene therapy is, I understand, the holy grail for genetic disorders. A successful gene therapy for Retts could put Daybue out of business.
But this fatal treatment related event for Neurogene has just emphasised how difficult it will be to bring a gene therapy competitor to Daybue to market. Who's going to put their child on a drug that can kill patients?
This news is undeniably sad new and a serious setback for a promising treatment for Retts.
But for any rational investor in Neuren it can't be viewed as anything other than good news. Daybue's position as the best and only treatment for Retts just got strengthened.
NEU Price at posting:
$12.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)